A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx

Exclusion Criteria

• •Clinically significant abnormalities in medical history, screening laboratory results, or physical examination that would render the participant unsuitable for inclusion
• •History of secondary hypertension (HTN)
• •The use of the following at time of screening and during the course of the study:
• •Other medications for the treatment of HTN (e.g., clonidine, guanfacine, guanabenz, alpha-methyldopa, hydralazine, minoxidil, diazoxide, renin inhibitors)
• •Medications that may cause hyperkalemia (e.g., cyclosporine or tacrolimus, pentamidine, trimethoprim-sulfamethoxazole, all heparins)
• •Oral or SC anticoagulants (e.g., warfarin, rivaroxaban, apixaban, heparin, lovenox)
• •Organic nitrate preparations (e.g., nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, or pentaerythritol)
• •Phosphodiesterase 5 inhibitors (e.g., sildenafil, tadalafil, vardenafil, avanafil)
• •Potassium-sparing diuretics (e.g., eplerenone, spironolactone, amiloride, triamterene)
• •Unstable/underlying cardiovascular disease defined as:
• •Any history of congestive heart failure (New York Heart Association \[NYHA\] class II-IV)
• •Any history of previous stroke, transient ischemic attack, unstable or stable angina pectoris, or myocardial infarction prior to screening
• •12-lead electrocardiogram (ECG) corrected using Fridericia's formula (QTcF) \> 450 milliseconds (msec) in males and \> 470 msec in females at screening, or a history or evidence of long QT syndrome
• •Any clinically significant active atrial or ventricular arrhythmias
• •Any history of coronary bypass or percutaneous coronary intervention